Office of Women’s Health director named
FDA names Kathleen Uhl as director of the Office of Women's Health, effective Dec. 15. Uhl has been with the Center for Drug Evaluation & Research since 1998, most recently serving as the team leader for the Pregnancy & Lactation Labeling Team in the Office of New Drugs. Uhl will replace Theresa Toigo, who took over as acting director of the women's health office after Susan Wood resigned in protest of FDA's handling of an OTC switch application for Barr's emergency contraceptive Plan B (1"The Pink Sheet" Sept. 6, 2005, p. 6)...
You may also be interested in...
FDA's handling of Barr's application to switch Plan B over the counter could elicit heightened external scrutiny of the agency's ability to make drug approval decisions based solely on science and public health
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.